Systemic therapy for cutaneous T-cell lymphoma: Who, when, what, and why? Journal Article


Authors: Virmani, P.; Hwang, S. H.; Hastings, J. G.; Haverkos, B. M.; Kohnken, B.; Gru, A. A.; Mishra, A.; Fabbro, S. K.; Horwitz, S. M.; Porcu, P.
Article Title: Systemic therapy for cutaneous T-cell lymphoma: Who, when, what, and why?
Abstract: Introduction: CTCL are rare neoplasms. Optimal care requires integrated use of diagnostic and treatment modalities spanning multiple specialties. Current instruments for patient risk stratification and disease measurement across all anatomical compartments are suboptimal. A common treatment dichotomy between early (Dermatology) and advanced stage (Hematology-Oncology) has hindered accrual of long term outcome data. Thus, important facts about natural history, such as frequency and determinants of stage progression, and the impact of specific treatment modalities on these endpoints, are not known. Areas covered: One of the most important decisions in the management of CTCL is when to start systemic therapy and what agents to use. This review provides background information to understand why systemic therapy is needed and what goals are currently achievable. Expert commentary: Risk-adapted approaches, based on better knowledge of host and tumor biology, and more accurate disease measurement tools are needed to optimize the use of specific systemic therapies. © 2016 Informa UK Limited, trading as Taylor & Francis Group.
Keywords: systemic therapy; staging; outcomes; mycosis fungoides; sezary syndrome; ctcl
Journal Title: Expert Review of Hematology
Volume: 10
Issue: 2
ISSN: 1747-4086
Publisher: Taylor & Francis Group  
Date Published: 2017-01-01
Start Page: 111
End Page: 121
Language: English
DOI: 10.1080/17474086.2017.1270201
PROVIDER: scopus
PUBMED: 27998183
DOI/URL:
Notes: Review -- Export Date: 2 March 2017 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Steven M Horwitz
    645 Horwitz
  2. Pooja   Virmani
    10 Virmani